[The preliminary study of Neuroform EZ stent in the treatment of severe intracranial atherosclerotic stenosis].

Objective: To evaluate the safety and clinical efficacy of Neuroform EZ stent in the treatment of severe intracranial atherosclerotic stenosis (ICAS). Methods: A total of 36 patients with severe ICAS receiving Neuroform EZ stent angioplasty were retrospectively analyzed at Beijing Anzhen Hospital from July 2018 to January 2020. Digital subtraction angiography (DSA) before endovascular intervention confirmed the diagnosis. Follow-up information was reviewed by neurologists at 30 days and 6 months after the procedure. The primary endpoints were transient ischemic attack (TIA), ischemic or hemorrhagic stroke and death caused by any reason within 30 days. Results: The overall technical success rate was 100%. The median stenosis rate was reduced from 93.6%±4.5% to 18.8%±11.2% (t=37.36,P<0.001).Primary endpoint event was not reported. During follow-up, one patient developed TIA and no death or ischemic stroke was observed. No in-stent restenosis at six months occurred. Conclusion: Neuroform EZ stent is safe and effective in patients with severe ICAS. However, perspective studies need to be operated for further validation via long-term follow-up.目的： 评价Neuroform EZ支架在重度动脉粥样硬化性颅内动脉狭窄患者治疗中的安全性和有效性。 方法： 回顾性分析2018年7月至2020年1月于首都医科大学附属北京安贞医院神经介入科采用Neuroform EZ支架进行治疗的36例重度动脉粥样硬化性颅内动脉狭窄患者资料（规范药物治疗下仍有缺血性卒中发作），所有患者术前行全脑数字减影血管造影（digital subtraction angiography，DSA）以明确诊断，术后30 d、6个月随访，主要终点事件定义为术后30 d内发生的短暂性脑缺血发作（transient ischemic attack，TIA）、出血性或缺血性卒中、任何原因引起的死亡。 结果： 36例患者支架置入成功率100%，支架置入后罪犯血管狭窄率由93.6%±4.5%降为18.8%±11.2%，差异有统计学意义（t =37.36，P<0.001）；主要终点事件发生率为0，术后6个月随访支架内再狭窄发生率为0。术后6个月内TIA发生率2.78%（1例），无缺血性卒中死亡病例。 结论： Neuroform EZ支架在规范药物治疗效果不佳的重度动脉粥样硬化性颅内动脉狭窄患者的治疗中安全有效，但仍需长期随访、多中心随机对照研究加以验证。.